Eurobio Scientific Société anonyme (ALERS.PA)
| Previous close | 14.76 |
| Open | 14.78 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 14.46 - 14.78 |
| 52-week range | 12.20 - 18.10 |
| Volume | |
| Avg. volume | 4,803 |
| Market cap | 148.447M |
| Beta (5Y monthly) | -0.33 |
| PE ratio (TTM) | 34.37 |
| EPS (TTM) | 0.43 |
| Earnings date | 10 Apr 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 30.00 |
GlobeNewswireEUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT®
EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENE EXPRESSION TEST FOR BREAST CANCER ENDOPREDICT® Expansion in the oncology segmentDevelopment of Eurobio Scientific proprietary product portfolioIncrease of international exposure Paris, 7th May 2024 – 06:30 pm Eurobio Scientific (FR0013240934, ALERS), (FR0013240934, ALERS, PEA-PME eligible), a leading French group in in vitro specialty medical diagnostics and life sciences, announces the signing on May 7th, 2024 of an agreement to acquire all
Globe NewswireEUROBIO SCIENTIFIC: 2023 ANNUAL RESULTS
2023 ANNUAL RESULTS Growth in Core Business and strategic deployment Core business1 revenues up 39% to €130m proprietary products account for 30% of revenues38% of revenues generated outside France Resilient results within a strategic transformation phaseFree cash flow of €26.4mNet financial debt reduced to €5.5m, with €89m cash position Paris, April 10, 2024 - 5.40pm - Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro medical diagnostics and life sciences, today annou
- Globe Newswire
Eurobio Scientific: FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP
FISCAL YEAR 2023, STRATEGIC TRANSFORMATION OF THE GROUP Continued total year growth in core business revenues, up 39%Successful deployment of the Group's strategy: Proprietary products up at 30% of revenuesInternationalization, with 38% of revenues now generated outside of France Acquisition of DID in Italy effective as of July 1st, 2023Acquisition of Alpha Biotech, GenDx distributor, effective as of January 3rd, 2024 Paris, January 30, 2024 – 5:45 pm Eurobio Scientific (FR0013240934, ALERS, PEA
